9. four. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL: Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration In comparison with Common Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv 2012, 5:90?7. 5. Elhmidi Y, Bleiziffer S, Piazza N, Hutter A, Opitz A, Hettich I, Kornek M, Ruge H, Brockmann G, Mazzitelli D, Lange R: Incidence and predictors of acute kidney injury in patients undergoing transcatheter aortic valve implantation. Am Heart J 2011, 161:735?39. 6. Khawaja MZ, Thomas M, Joshi A, Asrress KN, Wilson K, Bolter K, Young CP, Hancock J, Bapat V, Redwood S: The effects of VARC-defined acute kidney injury right after transcatheter aortic valve implantation (TAVI) making use of the Edwards bioprosthesis. Euro Interv 2012, 8:563?70. 7. Nuis RJ, Van Mieghem NM, Tzikas A, Piazza N, Otten AM, Cheng J, van Domburg RT, Betjes M, Serruys PW, de Jaegere PP: Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in sufferers undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2011, 77:881?89. 8. Podolecka E, Chmielak Z, Demkow M, Michalek P, Ksiezycka-Majczynska E, Chojnowska SL, Hryniewiecki T, Kusmierski K, Juraszynski Z, Czerwinska K, Sitkowska-Rysiak E, Stpiska J, Ruyllo W, Witkowski A: Does contrast agent injection in the course of trans-catheter aortic valve implantation negatively have an effect on kidney function? Kardiol Pol 2011, 69:251?55. 9. Saia F, Ciuca C, Taglieri N, Marrozzini C, Savini C, Bordoni B, Dall’ara G, Moretti C, Pilato E, Martin-Suarez S, Petridis FD, Di Bartolomeo R, Branzi A, Marzocchi A: Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome.(Diacetoxyiodo)benzene Data Sheet Int J Cardiol 2013, 168:1034?040. ten. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW: Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Analysis Consortium.146683-25-2 manufacturer Eur Heart J 2011, 32:205?17.PMID:23399686 11. Genereux P, Kodali SK, Green P, Paradis JM, Daneault B, Rene G, Hueter I, Georges I, Kirtane A, Hahn RT, Smith C, Leon MB, Williams MR: Incidence and impact of acute kidney injury right after transcatheter aortic valve replacement making use of the new valve academic investigation consortium criteria. Am J Cardiol 2013, 111:100?05. 12. Nuis RJ, Rodes-Cabau J, Sinning JM, van Garsse L, Kefer J, Bosmans J, Dager AE, van Mieghem N, Urena M, Nickenig G, Werner N, Maessen J, Astarci P,The trial is ongoing. Presently 41 patients happen to be recruited.Abbreviations AKI: acute kidney injury; CE: Conformit?Europ nne; CEC: clinical event committee; CKD: chronic kidney illness; DSMB: data safety monitoring board; eGFR: estimated glomerular filtration price; ITT: intent-to-treat; MACE: significant adverse clinical events; MDRD: Modification of Diet program in Renal Illness TAVI, transcatheter aortic valve implantation; VARC-2: Valve Academic Investigation Consortium-2. Competing interest A.F. serves as a consultant and proctor of both Medtronic Cardiovascular and Edwards Lifesciences. All other authors declare that they’ve no competing interests. Authors’ contributions YA and EBA are joint head investigators for t.
